A Study of ZN-c3 in Women With Recurrent or Persistent Uterine Serous Carcinoma
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
This is a Phase 2 study to evaluate the clinical activity, safety, pharmacokinetics (PK), and
related biomarkers of ZN-c3 in adult women with recurrent or persistent uterine serous
carcinoma (USC).